miR-29b and miR-198 overexpression in CD8+ T cells of renal cell carcinoma patients down-modulates JAK3 and MCL-1 leading to immune dysfunction
Authors:
- Margherita GiganteMGMargherita Gigante
- Paola PontrelliPaola Pontrelli
- Wolfgang HerrWHWolfgang Herr
- Maddalena GiganteMGMaddalena Gigante
- Morena D’aVeniaMDMorena D’aVenia
- Gianluigi ZazaGianluigi Zaza
- Elisabetta CavalcantiECElisabetta Cavalcanti
- Matteo AccetturoMAMatteo Accetturo
- Giuseppe LucarelliGiuseppe Lucarelli
- Giuseppe CarrieriGCGiuseppe Carrieri
- Michele BattagliaMBMichele Battaglia
- Walter J. StorkusWalter J. Storkus
Open Access
- 11 April 2016
- journal article
- research article
- Published by Springer Nature in Journal of Translational Medicine
- Vol. 14 (1) , 84
Abstract
Mammalian microRNAs (miR) regulate the expression of genes relevant for the development of adaptive and innate immunity against cancer. Since T cell dysfunction has previously been reported in patients with renal cell carcinoma (RCC; clear cell type), we aimed to analyze these immune cells for genetic and protein differences when compared to normal donor T cells freshly after isolation and 35 days after in vitro stimulation (IVS) with HLA-matched RCC tumor cells. We investigated gene expression profiles of tumor-reactive CD8+ T cells obtained from RCC patient and compared with their HLA-matched healthy sibling donors using a microarray approach. In addition, miRNAs analysis was performed in a validation cohort of peripheral blood CD8+ T cells from 25 RCC patients compared to 15 healthy volunteers. We observed that CD8+ T cells from RCC patients expressed reduced levels of anti-apoptotic and proliferation-associated gene products when compared with normal donor T cells both pre- and post-IVS. In particular, JAK3 and MCL-1 were down-regulated in patient CD8+ T cells versus their normal counterparts, likely due to defective suppressor activity of miR-29b and miR-198 in RCC CD8+ T cells. Indeed, specific inhibition of miR-29b or miR-198 in peripheral blood mononuclear cells (PBMCs) isolated from RCC patients, resulted in the up-regulation of JAK3 and MCL-1 proteins and significant improvement of cell survival in vitro. Our results suggest that miR-29b and miR-198 dysregulation in RCC patient CD8+ T cells is associated with dysfunctional immunity and foreshadow the development of miR-targeted therapeutics to correct such T cell defects in vivo.Keywords
This publication has 44 references indexed in Scilit:
- The emerging role of miRNAs in combined cancer therapyExpert Opinion on Biological Therapy, 2015
- microRNAs function in CD8+T cell biologyJournal of Leukocyte Biology, 2015
- MicroRNAome genome: A treasure for cancer diagnosis and therapyCA: A Cancer Journal for Clinicians, 2014
- Programming cancer cells for high expression levels of Mcl1EMBO Reports, 2013
- miRNA expression profiling of lung adenocarcinomas: correlation with mutational statusLaboratory Investigation, 2010
- Dicer controls CD8+T-cell activation, migration, and survivalProceedings of the National Academy of Sciences, 2010
- Identification of a MicroRNA Panel for Clear-cell Kidney CancerUrology, 2010
- Janus kinases in immune cell signalingImmunological Reviews, 2009
- Disease-associated Bias in T Helper Type 1 (Th1)/Th2 CD4+ T Cell Responses Against MAGE-6 in HLA-DRB10401+ Patients With Renal Cell Carcinoma or MelanomaJournal of Experimental Medicine, 2002
- T cells from Jak3-deficient mice have intact TCR signaling, but increased apoptosisThe Journal of Immunology, 1997